Clinical aspects of B vitamin use
DOI: 10.32364/2587-6821-2021-5-9-579-585
E.V. Biryukova1, M.V. Shinkin2
1A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow,
Russian Federation
2A.S. Loginov Moscow Clinical Research Center, Moscow, Russian Federation
Polyneuropathy is a common disorder of the peripheral nervous system. Diabetic neuropathy is the most common and most studied variant of polyneuropathies. The duration of carbohydrate metabolism disorders and inadequate glycemic control are risk factors for nervous system damage in diabetes. Distal neuropathy is a common type of neuropathy associated with diabetes. Interconnecting pathological mechanisms initiated by high blood glucose result in the damage of peripheral nerve fibers. Clinical presentations of distal neuropathy depend on the damage of proximal or distal and sensory or motor nerve fibers and the involvement of the vegetative nervous system. Medications improving metabolic processes in nerve fibers and reducing the severity of peripheral nerve damage are beneficial in addressing the harmful effects of hyperglycemia. Neurometabolic therapy includes thiamine, pyridoxine, and cyanocobalamin (B vitamins) which provide neurotropic effects. B vitamins acting as c o-factors in many enzymatic reactions significantly affect the normal functioning of nerve fibers. B vitamins are effective and safe agents used to treat peripheral nervous system diseases for many years. This paper discusses the potential use of B vitamins for diabetic neuropathy and the COVID-19 treatment and rehabilitation.
Keywords: polyneuropathy, hyperglycemia, diabetes, distal neuropathy, B vitamins, thiamine, pyridoxine, cyanocobalamin, COVID-19.
For citation: Biryukova E.V., Shinkin M.V. Clinical aspects of B vitamin use. Russian Medical Inquiry. 2021;5(9):579–585 (in Russ.). DOI: 10.32364/2587-6821-2021-5-9-579-585.
About the authors:
Elena V. Biryukova — Dr. Sc. (Med.), Professor, professor of the Department of Endocrinology and Diabetes, A.I. Yevdokimov Moscow State University of Medicine and Dentistry; 20/1, Delegatskaya str., Moscow, 127473, Russian Federation; ORCID iD 0000-0001-9007-4123.
Mikhail V. Shinkin — researcher of the Division of Endocrine and Metabolic Diseases, A.S. Loginov Moscow Clinical Research Center; 86, Entuziastov road, Moscow, 111123, Russian Federation; ORCID iD 0000-0003-1548-1487.
Contact information: Elena V. Biryukova, e-mail: lena@obsudim.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 09.07.2021.
Revised 03.08.2021.
Accepted 26.08.2021.
References
1. Бородулина И.В., Рачин А.П. Полинейропатии в практике врача: особенности патогенеза, клиники и современные подходы к лечению болевых и безболевых форм. РМЖ. 2016;25:1705–1710. [Borodulina I.V., Rachin A.P. Polyneuropathies: pathogenesis, clinical manifestations, and current treatment approaches to painful and painless conditions. RMJ. 2016;25:1705–1710 (in Russ.)].
2. Volmer-Thole M., Lobmann R. Neuropathy and Diabetic Foot Syndrome. Int J Mol Sci. 2016;17(6):917. DOI: 10.3390/ijms17060917.
3. Zilliox L.A. Diabetes and Peripheral Nerve Disease. Clin Geriatr Med. 2021;37(2):253–267. DOI: 10.1016/j.cger.2020.12.001.
4. Stino A.M., Smith A.G. Peripheral neuropathy in prediabetes and the metabolic syndrome. J Diabetes Investig. 2017;8(5):646–655. DOI: 10.1111/jdi.12650.
5. Pop-Busui R., Boulton A.J., Feldman E.L. et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154. DOI: 10.2337/dc16-2042.
6. Клинические рекомендации «Алгоритмы специализированной медицинской помощи больным сахарным диабетом» Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й выпуск. М.; 2019. [Clinical guidelines "Algorithms for specialized medical care for patients with diabetes mellitus" Edited by I.I. Dedova, M.V. Shestakova, A.Yu. Mayorov. 9th edition. M.; 2019 (in Russ.)].
7. Carmichael J., Fadavi H., Ishibashi F. et al. Advances in Screening, Early Diagnosis and Accurate Staging of Diabetic Neuropathy. Front Endocrinol (Lausanne). 2021;12:671257. DOI: 10.3389/fendo.2021.671257.
8. Albers J.W., Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014;14(8):473. DOI: 10.1007/s11910-014-0473-5.
9. Садырин А.В., Карпова М.И., Долганов М.В. Диабетическая полинейропатия: вопросы патогенеза и возможности лечения. РМЖ. 2016;1:47–50. [Sadyrin A.V., Karpova M.I., Dolganov M.V. Diabetic polyneuropathy: issues of pathogenesis and treatment options. RMJ. 2016;1:47–50 (in Russ.)].
10. Dyck P.J., Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review. J Neuropathol Exp Neurol. 1996;55(12):1181–1193. DOI: 10.1097/00005072-199612000-00001.
11. Sheetz M.J., King G.L. Molecular Understanding of Hyperglycemia’s Adverse Effects for Diabetic Complications. JAMA. 2002;288(20):2579–2588. DOI: 10.1001/jama.288.20.2579.
12. Introduction: Standards of Medical Care in Diabetes — 2020. Diabetes Care. 2020;43(Suppl 1):S1-S2. DOI: 10.2337/dc20-Sint.
13. Ang L., Jaiswal M., Martin C., Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14(9):528. DOI: 10.1007/s11892-014-0528-7.
14. Jayabalan B., Low L.L. Vitamin B supplementation for diabetic peripheral neuropathy. Singapore Med J. 2016;57(2):55–59. DOI: 10.11622/smedj.2016027.
15. Calderón-Ospina C.A., Nava-Mesa M.O. B Vitamins in the nervous system: Current knowledge of the biochemical modes of action and synergies of thiamine, pyridoxine, and cobalamin. CNS Neurosci Ther. 2020;26(1):5–13. DOI: 10.1111/cns.13207.
16. Павлов Ч.С., Дамулин И.В., Шульпекова Ю.О., Андреев Е.А. Неврологические расстройства при дефиците витамина В12. Терапевтический архив. 2019;91(4):122–129. DOI: 10.26442/00403660.2019.04.000116. [Pavlov Ch.S., Damulin I.V., Shulpekova Yu.O., Andreyev E.A. Neurological disorders in vitamin B12 deficiency. Therapeutic. Archive. 2019;91(4):122–129 (in Russ.)]. DOI: 10.26442/00403660.2019.04.000116.
17. Stein J., Geisel J., Obeid R. Association between neuropathy and B-vitamins: A systematic review and meta-analysis. Eur J Neurol. 2021;28(6):2054–2064. DOI: 10.1111/ene.14786.
18. Staff N.P., Windebank A.J. Peripheral neuropathy due to vitamin deficiency, toxins, and medications. Continuum (Minneap Minn). 2014;20:1293–1306. DOI: 10.1212/01.CON.0000455880.06675.5a.
19. Пилипович А.А. Применение витаминов группы В в терапии полинейропатии разного генеза. CardioСоматика. 2018;9(2):36–42. DOI: 10.26442/2221-7185_2018.2.36-42. [Pilipovich A.A. The use of B vitamins in the treatment of polyneuropathy of different genesis. Cardiosomatics. 2018;9(2):36–42 (in Russ.)]. DOI: 10.26442/2221-7185_2018.2.36-42.
20. Whitfield K.C., Bourassa M.W., Adamolekun B. et al. Thiamine deficiency disorders: diagnosis, prevalence, and a roadmap for global control programs. Ann N Y Acad Sci. 2018;1430(1):3–43. DOI: 10.1111/nyas.13919.
21. Zhao Y., Wu Y., Hu H. et al. Downregulation of transketolase activity is related to inhibition of hippocampal progenitor cell proliferation induced by thiamine deficiency. Biomed Res Int. 2014;2014:572915. DOI: 10.1155/2014/572915.
22. Pacal L., Kuricova K., Kankova K. Evidence for altered thiamine metabolism in diabetes: Is there a potential to oppose gluco- and lipotoxicity by rational supplementation? World J Diabetes. 2014;5(3):288–295. DOI: 10.4239/wjd.v5.i3.288.
23. Amirani E., Aghadavod E., Shafabakhsh R. et al. Anti-inflammatory and antioxidative effects of thiamin supplements in patients with gestational diabetes mellitus. J Matern Fetal Neonatal Med. 2020:1–6. DOI: 10.1080/14767058.2020.1779212.
24. Merigliano C., Mascolo E., Burla R. et al. The Relationship Between Vitamin B6, Diabetes and Cancer. Front Genet. 2018;9:388. DOI: 10.3389/fgene.2018.00388.
25. Moreno-Navarrete J. M., Jove M., Ortega F. et al. Metabolomics uncovers the role of adipose tissue PDXK in adipogenesis and systemic insulin sensitivity. Diabetologia. 2016;59(4):822–832. DOI: 10.1007/s00125-016-3863-1.
26. Liu Z., Li P., Zhao Z.H. et al. Vitamin B6 prevents endothelial dysfunction, insulin resistance, and hepatic lipid accumulation in apoe (-/-) mice fed with high-fat diet. J. Diabetes Res. 2016;2016:1748065. DOI: 10.1155/2016/1748065.
27. Damiao C.P., Rodrigues A.O., Pinheiro M.F. et al. Prevalence of vitamin B12 deficiency in type 2 diabetic patients using metformin: a cross-sectional study. Sao Paulo Med J. 2016;134(6):473–479. DOI: 10.1590/1516-3180.2015.01382111.
28. Aroda V.R., Edelstein S.L., Goldberg R.B. et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754–1761. DOI: 10.1210/jc.2015-3754.
29. Beltramo E., Mazzeo A., Porta M. Thiamine and diabetes: back to the future? Acta Diabetol. 2021. DOI: 10.1007/s00592-021-01752-4.
30. Dos Santos L.M.J. Can vitamin B12 be an adjuvant to COVID-19 treatment? GSC Biological and Pharmaceutical Sciences. 2020;11(03):001–005. DOI: 10.30574/gscbps.2020.11.3.0155.
31. Felsenstein S., Herbert J.A., McNamara P.S., Hedrich C.M. COVID-19: immunology and treatment options. Clin Immunol. 2020;215:108448. DOI: 10.1016/j.clim.2020.108448.
32. Громова О.А., Торшин И.Ю., Чучалин А.Г. О перспективах применения тиамина, пиридоксина и цианокобаламина в комплексной терапии и реабилитации пациентов с COVID-19. Пульмонология. 2021;31(3):355–363. DOI: 10.18093/0869-0189-2021-31-3-355-363.[Gromova O.A., Torshin I.Yu., Chuchalin A.G. On the prospects for the use of thiamine, pyridoxine, and cyanocobalamin in the complex therapy and rehabilitation of patients with COVID-19. Pul’monologiya. 2021;31(3):355–363 (in Russ.)]. DOI: 10.18093/0869-0189-2021-31-3-355-363.
33. Feehan J., Apostolopoulos V. Is COVID-19 the worst pandemic? Maturitas. 2021;149:56–58. DOI: 10.1016/j.maturitas.2021.02.001.
34. Feehan J., de Courten M., Apostolopoulos V., de Courten B. Nutritional Interventions for COVID-19: A Role for Carnosine? Nutrients. 2021;13(5):1463. DOI: 0.3390/nu13051463.
35. Kumrungsee T., Zhang P., Chartkul M. et al. Potential Role of Vitamin B6 in Ameliorating the Severity of COVID-19 and Its Complications. Front. Nutr. 2020;7:562051. DOI: 10.3389/fnut.2020.562051.
36. Narayanan N., Nair D.T. Vitamin B12 may inhibit RNA-dependent-RNA polymerase activity of nsp12 from the SARS-CoV-2 virus. IUBMB Life. 2020;72(10):2112–2120. DOI: 10.1002/iub.2359.
37. Vatsalya V., Li F., Frimodig J.C. et al. Therapeutic prospects for Th-17 cell immune storm syndrome and neurological symptoms in COVID-19: thiamine efficacy and safety, in-vitro evidence and pharmacokinetic profile. medRxiv: the preprint server for health sciences, 2020.08.23.20177501. DOI: 10.1101/2020.08.23.20177501.
38. Kobzar G., Mardla V., Rätsep I., Samel N. Effect of vitamin B(6) vitamers on platelet aggregation. Platelets. 2009;20(2):120–124. DOI: 10.1080/09537100802687674.
39. Al Sulaiman K., Aljuhani O., Al Dossari M. et al. Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study. Crit Care. 2021;25(1):223. DOI: 10.1186/s13054-021-03648-9.
40. Zheng Y., Ma Y., Zhang J., Xie X. COVID-19 and the cardiovascular system. Nature Reviews Cardiology. 2020;17(5):259–260. DOI: 10.1038/s41569-020-0360-5.
41. Yuan S., Mason A.M., Carter P. et al. Homocysteine, B vitamins, and cardiovascular disease: a Mendelian randomization study. BMC Med. 2021;19(1):97. DOI: 10.1186/s12916-021-01977-8.
42. Selhub J., Bagley L.C., Miller J., Rosenberg I.H. B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr. 2000;71(2):614S–620S. DOI: 10.1093/ajcn/71.2.614s.
43. Kataria N., Yadav P., Kumar R. et al. Effect of Vitamin B6, B9, and B12 Supplementation on Homocysteine Level and Cardiovascular Outcomes in Stroke Patients: A Meta-Analysis of Randomized Controlled Trials. Cureus. 2021;13(5):e14958. DOI: 10.7759/cureus.14958.
44. Mauro G.L., Martorana U., Cataldo P. et al. Vitamin B12 in low back pain: a randomised, double-blind, placebo-controlled study. Eur Rev Med Pharmacol Sci. 2000;4(3):53–58.
45. Lopes S.C., Gadelha D.D., Carvalho M.D. et al. Vitamin B12 deficiency: metabolic effects, clinical evaluation, and treatment. Revista de Medicina da UFC. 2019;59(2):40–49. DOI: 10.20513/2447-6595.2019v59n2p40-49.
46. Procter B.C., Ross C., Pickard V. et al. Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Rev Cardiovasc Med. 2020;21(4):611–614. DOI: 10.31083/j.rcm.2020.04.260.
47. Tan C.W., Ho L.P., Kalimuddin S. et al. Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19). Nutrition. 2020;79–80:111017. DOI: 10.1016/j.nut.2020.111017.
48. Головачева В.А., Головачева А.А., Голубев В.Л., Зиновьева О.Е. Ведение пациентов с диабетической полиневропатией в условиях пандемии COVID-19. Эффективная фармакотерапия. 2021;17(10):20–26. DOI: 10.33978/2307-3586-2021-17-10-20-26. [Golovacheva V.A., Golovacheva A.A., Golubev V.L., O.Ye. Zinovyeva. Management of Patients with Diabetic Polyneuropathy in the Conditions of the COVID-19 Pandemic. Effective Pharmacotherapy. 2021;17(10):20–26 (in Russ.)]. DOI: 10.33978/2307-3586-2021-17-10-20-26.
49. Odriozola A., Ortega L., Martinez L. et al. Widespread sensory neuropathy in diabetic patients hospitalized with severe COVID-19 infection. Diabetes Res. Clin. Pract. 2021;172:108631. DOI: 10.1016/j.diabres.2020.108631.
50. Pitocco D., Viti L., Santoliquido A. et al. Diabetic neuropathy: a risk factor for severe COVID-19? Acta Diabetol. 2021;58(5):669–670. DOI: 10.1007/s00592-020-01658-7.
51. Derin S., Koseoglu S., Sahin C., Sahan M. Effect of vitamin B12 deficiency on olfactory function. Int. Forum Allergy Rhinol. 2016;6(10):1051–1055. DOI: 10.1002/alr.21790.
52. Артеменко А.Р., Данилов А.Б., Плиева А.М. Нарушение обоняния у больных COVID-19. Российский неврологический журнал. 2020;25(6):4–11. DOI: 10.30629/2658-7947-2020-25-6-4-11. [Аrtemenkо A.R., Danilov A.B., Plieva A.M. Smell dysfunction in patients with COVID-19. Russian neurological journal. 2020;25(6):4–11 (in Russ.)]. DOI: 10.30629/2658-7947-2020-25-6-4-11.
53. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). 11-е изд., М.: Министерство здравоохранения Российской Федерации; 2021. [Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) 11th ed., М.: Ministry of Health of the Russian Federation; 2021 (in Russ.)].
54. Kory P., Meduri G.U., Iglesias J. et al. Clinical and Scientific Rationale for the "MATH+» Hospital Treatment Protocol for COVID-19. J Intensive Care Med. 2021;36(2):135–156. DOI: 10.1177/0885066620973585.
55. Front-Line COVID-19 Critical Care Alliance. (Electronic resource.) URL: https://covid19criticalcare.com (access date: 07.07.2021).
2. Volmer-Thole M., Lobmann R. Neuropathy and Diabetic Foot Syndrome. Int J Mol Sci. 2016;17(6):917. DOI: 10.3390/ijms17060917.
3. Zilliox L.A. Diabetes and Peripheral Nerve Disease. Clin Geriatr Med. 2021;37(2):253–267. DOI: 10.1016/j.cger.2020.12.001.
4. Stino A.M., Smith A.G. Peripheral neuropathy in prediabetes and the metabolic syndrome. J Diabetes Investig. 2017;8(5):646–655. DOI: 10.1111/jdi.12650.
5. Pop-Busui R., Boulton A.J., Feldman E.L. et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154. DOI: 10.2337/dc16-2042.
6. Клинические рекомендации «Алгоритмы специализированной медицинской помощи больным сахарным диабетом» Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й выпуск. М.; 2019. [Clinical guidelines "Algorithms for specialized medical care for patients with diabetes mellitus" Edited by I.I. Dedova, M.V. Shestakova, A.Yu. Mayorov. 9th edition. M.; 2019 (in Russ.)].
7. Carmichael J., Fadavi H., Ishibashi F. et al. Advances in Screening, Early Diagnosis and Accurate Staging of Diabetic Neuropathy. Front Endocrinol (Lausanne). 2021;12:671257. DOI: 10.3389/fendo.2021.671257.
8. Albers J.W., Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014;14(8):473. DOI: 10.1007/s11910-014-0473-5.
9. Садырин А.В., Карпова М.И., Долганов М.В. Диабетическая полинейропатия: вопросы патогенеза и возможности лечения. РМЖ. 2016;1:47–50. [Sadyrin A.V., Karpova M.I., Dolganov M.V. Diabetic polyneuropathy: issues of pathogenesis and treatment options. RMJ. 2016;1:47–50 (in Russ.)].
10. Dyck P.J., Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review. J Neuropathol Exp Neurol. 1996;55(12):1181–1193. DOI: 10.1097/00005072-199612000-00001.
11. Sheetz M.J., King G.L. Molecular Understanding of Hyperglycemia’s Adverse Effects for Diabetic Complications. JAMA. 2002;288(20):2579–2588. DOI: 10.1001/jama.288.20.2579.
12. Introduction: Standards of Medical Care in Diabetes — 2020. Diabetes Care. 2020;43(Suppl 1):S1-S2. DOI: 10.2337/dc20-Sint.
13. Ang L., Jaiswal M., Martin C., Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14(9):528. DOI: 10.1007/s11892-014-0528-7.
14. Jayabalan B., Low L.L. Vitamin B supplementation for diabetic peripheral neuropathy. Singapore Med J. 2016;57(2):55–59. DOI: 10.11622/smedj.2016027.
15. Calderón-Ospina C.A., Nava-Mesa M.O. B Vitamins in the nervous system: Current knowledge of the biochemical modes of action and synergies of thiamine, pyridoxine, and cobalamin. CNS Neurosci Ther. 2020;26(1):5–13. DOI: 10.1111/cns.13207.
16. Павлов Ч.С., Дамулин И.В., Шульпекова Ю.О., Андреев Е.А. Неврологические расстройства при дефиците витамина В12. Терапевтический архив. 2019;91(4):122–129. DOI: 10.26442/00403660.2019.04.000116. [Pavlov Ch.S., Damulin I.V., Shulpekova Yu.O., Andreyev E.A. Neurological disorders in vitamin B12 deficiency. Therapeutic. Archive. 2019;91(4):122–129 (in Russ.)]. DOI: 10.26442/00403660.2019.04.000116.
17. Stein J., Geisel J., Obeid R. Association between neuropathy and B-vitamins: A systematic review and meta-analysis. Eur J Neurol. 2021;28(6):2054–2064. DOI: 10.1111/ene.14786.
18. Staff N.P., Windebank A.J. Peripheral neuropathy due to vitamin deficiency, toxins, and medications. Continuum (Minneap Minn). 2014;20:1293–1306. DOI: 10.1212/01.CON.0000455880.06675.5a.
19. Пилипович А.А. Применение витаминов группы В в терапии полинейропатии разного генеза. CardioСоматика. 2018;9(2):36–42. DOI: 10.26442/2221-7185_2018.2.36-42. [Pilipovich A.A. The use of B vitamins in the treatment of polyneuropathy of different genesis. Cardiosomatics. 2018;9(2):36–42 (in Russ.)]. DOI: 10.26442/2221-7185_2018.2.36-42.
20. Whitfield K.C., Bourassa M.W., Adamolekun B. et al. Thiamine deficiency disorders: diagnosis, prevalence, and a roadmap for global control programs. Ann N Y Acad Sci. 2018;1430(1):3–43. DOI: 10.1111/nyas.13919.
21. Zhao Y., Wu Y., Hu H. et al. Downregulation of transketolase activity is related to inhibition of hippocampal progenitor cell proliferation induced by thiamine deficiency. Biomed Res Int. 2014;2014:572915. DOI: 10.1155/2014/572915.
22. Pacal L., Kuricova K., Kankova K. Evidence for altered thiamine metabolism in diabetes: Is there a potential to oppose gluco- and lipotoxicity by rational supplementation? World J Diabetes. 2014;5(3):288–295. DOI: 10.4239/wjd.v5.i3.288.
23. Amirani E., Aghadavod E., Shafabakhsh R. et al. Anti-inflammatory and antioxidative effects of thiamin supplements in patients with gestational diabetes mellitus. J Matern Fetal Neonatal Med. 2020:1–6. DOI: 10.1080/14767058.2020.1779212.
24. Merigliano C., Mascolo E., Burla R. et al. The Relationship Between Vitamin B6, Diabetes and Cancer. Front Genet. 2018;9:388. DOI: 10.3389/fgene.2018.00388.
25. Moreno-Navarrete J. M., Jove M., Ortega F. et al. Metabolomics uncovers the role of adipose tissue PDXK in adipogenesis and systemic insulin sensitivity. Diabetologia. 2016;59(4):822–832. DOI: 10.1007/s00125-016-3863-1.
26. Liu Z., Li P., Zhao Z.H. et al. Vitamin B6 prevents endothelial dysfunction, insulin resistance, and hepatic lipid accumulation in apoe (-/-) mice fed with high-fat diet. J. Diabetes Res. 2016;2016:1748065. DOI: 10.1155/2016/1748065.
27. Damiao C.P., Rodrigues A.O., Pinheiro M.F. et al. Prevalence of vitamin B12 deficiency in type 2 diabetic patients using metformin: a cross-sectional study. Sao Paulo Med J. 2016;134(6):473–479. DOI: 10.1590/1516-3180.2015.01382111.
28. Aroda V.R., Edelstein S.L., Goldberg R.B. et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754–1761. DOI: 10.1210/jc.2015-3754.
29. Beltramo E., Mazzeo A., Porta M. Thiamine and diabetes: back to the future? Acta Diabetol. 2021. DOI: 10.1007/s00592-021-01752-4.
30. Dos Santos L.M.J. Can vitamin B12 be an adjuvant to COVID-19 treatment? GSC Biological and Pharmaceutical Sciences. 2020;11(03):001–005. DOI: 10.30574/gscbps.2020.11.3.0155.
31. Felsenstein S., Herbert J.A., McNamara P.S., Hedrich C.M. COVID-19: immunology and treatment options. Clin Immunol. 2020;215:108448. DOI: 10.1016/j.clim.2020.108448.
32. Громова О.А., Торшин И.Ю., Чучалин А.Г. О перспективах применения тиамина, пиридоксина и цианокобаламина в комплексной терапии и реабилитации пациентов с COVID-19. Пульмонология. 2021;31(3):355–363. DOI: 10.18093/0869-0189-2021-31-3-355-363.[Gromova O.A., Torshin I.Yu., Chuchalin A.G. On the prospects for the use of thiamine, pyridoxine, and cyanocobalamin in the complex therapy and rehabilitation of patients with COVID-19. Pul’monologiya. 2021;31(3):355–363 (in Russ.)]. DOI: 10.18093/0869-0189-2021-31-3-355-363.
33. Feehan J., Apostolopoulos V. Is COVID-19 the worst pandemic? Maturitas. 2021;149:56–58. DOI: 10.1016/j.maturitas.2021.02.001.
34. Feehan J., de Courten M., Apostolopoulos V., de Courten B. Nutritional Interventions for COVID-19: A Role for Carnosine? Nutrients. 2021;13(5):1463. DOI: 0.3390/nu13051463.
35. Kumrungsee T., Zhang P., Chartkul M. et al. Potential Role of Vitamin B6 in Ameliorating the Severity of COVID-19 and Its Complications. Front. Nutr. 2020;7:562051. DOI: 10.3389/fnut.2020.562051.
36. Narayanan N., Nair D.T. Vitamin B12 may inhibit RNA-dependent-RNA polymerase activity of nsp12 from the SARS-CoV-2 virus. IUBMB Life. 2020;72(10):2112–2120. DOI: 10.1002/iub.2359.
37. Vatsalya V., Li F., Frimodig J.C. et al. Therapeutic prospects for Th-17 cell immune storm syndrome and neurological symptoms in COVID-19: thiamine efficacy and safety, in-vitro evidence and pharmacokinetic profile. medRxiv: the preprint server for health sciences, 2020.08.23.20177501. DOI: 10.1101/2020.08.23.20177501.
38. Kobzar G., Mardla V., Rätsep I., Samel N. Effect of vitamin B(6) vitamers on platelet aggregation. Platelets. 2009;20(2):120–124. DOI: 10.1080/09537100802687674.
39. Al Sulaiman K., Aljuhani O., Al Dossari M. et al. Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study. Crit Care. 2021;25(1):223. DOI: 10.1186/s13054-021-03648-9.
40. Zheng Y., Ma Y., Zhang J., Xie X. COVID-19 and the cardiovascular system. Nature Reviews Cardiology. 2020;17(5):259–260. DOI: 10.1038/s41569-020-0360-5.
41. Yuan S., Mason A.M., Carter P. et al. Homocysteine, B vitamins, and cardiovascular disease: a Mendelian randomization study. BMC Med. 2021;19(1):97. DOI: 10.1186/s12916-021-01977-8.
42. Selhub J., Bagley L.C., Miller J., Rosenberg I.H. B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr. 2000;71(2):614S–620S. DOI: 10.1093/ajcn/71.2.614s.
43. Kataria N., Yadav P., Kumar R. et al. Effect of Vitamin B6, B9, and B12 Supplementation on Homocysteine Level and Cardiovascular Outcomes in Stroke Patients: A Meta-Analysis of Randomized Controlled Trials. Cureus. 2021;13(5):e14958. DOI: 10.7759/cureus.14958.
44. Mauro G.L., Martorana U., Cataldo P. et al. Vitamin B12 in low back pain: a randomised, double-blind, placebo-controlled study. Eur Rev Med Pharmacol Sci. 2000;4(3):53–58.
45. Lopes S.C., Gadelha D.D., Carvalho M.D. et al. Vitamin B12 deficiency: metabolic effects, clinical evaluation, and treatment. Revista de Medicina da UFC. 2019;59(2):40–49. DOI: 10.20513/2447-6595.2019v59n2p40-49.
46. Procter B.C., Ross C., Pickard V. et al. Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Rev Cardiovasc Med. 2020;21(4):611–614. DOI: 10.31083/j.rcm.2020.04.260.
47. Tan C.W., Ho L.P., Kalimuddin S. et al. Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19). Nutrition. 2020;79–80:111017. DOI: 10.1016/j.nut.2020.111017.
48. Головачева В.А., Головачева А.А., Голубев В.Л., Зиновьева О.Е. Ведение пациентов с диабетической полиневропатией в условиях пандемии COVID-19. Эффективная фармакотерапия. 2021;17(10):20–26. DOI: 10.33978/2307-3586-2021-17-10-20-26. [Golovacheva V.A., Golovacheva A.A., Golubev V.L., O.Ye. Zinovyeva. Management of Patients with Diabetic Polyneuropathy in the Conditions of the COVID-19 Pandemic. Effective Pharmacotherapy. 2021;17(10):20–26 (in Russ.)]. DOI: 10.33978/2307-3586-2021-17-10-20-26.
49. Odriozola A., Ortega L., Martinez L. et al. Widespread sensory neuropathy in diabetic patients hospitalized with severe COVID-19 infection. Diabetes Res. Clin. Pract. 2021;172:108631. DOI: 10.1016/j.diabres.2020.108631.
50. Pitocco D., Viti L., Santoliquido A. et al. Diabetic neuropathy: a risk factor for severe COVID-19? Acta Diabetol. 2021;58(5):669–670. DOI: 10.1007/s00592-020-01658-7.
51. Derin S., Koseoglu S., Sahin C., Sahan M. Effect of vitamin B12 deficiency on olfactory function. Int. Forum Allergy Rhinol. 2016;6(10):1051–1055. DOI: 10.1002/alr.21790.
52. Артеменко А.Р., Данилов А.Б., Плиева А.М. Нарушение обоняния у больных COVID-19. Российский неврологический журнал. 2020;25(6):4–11. DOI: 10.30629/2658-7947-2020-25-6-4-11. [Аrtemenkо A.R., Danilov A.B., Plieva A.M. Smell dysfunction in patients with COVID-19. Russian neurological journal. 2020;25(6):4–11 (in Russ.)]. DOI: 10.30629/2658-7947-2020-25-6-4-11.
53. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). 11-е изд., М.: Министерство здравоохранения Российской Федерации; 2021. [Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) 11th ed., М.: Ministry of Health of the Russian Federation; 2021 (in Russ.)].
54. Kory P., Meduri G.U., Iglesias J. et al. Clinical and Scientific Rationale for the "MATH+» Hospital Treatment Protocol for COVID-19. J Intensive Care Med. 2021;36(2):135–156. DOI: 10.1177/0885066620973585.
55. Front-Line COVID-19 Critical Care Alliance. (Electronic resource.) URL: https://covid19criticalcare.com (access date: 07.07.2021).
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
